Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2023; 11(5): 1058-1067
Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1058
Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer
Jian-Jing Liang, Wen-Jing Feng, Ru Li, Run-Tao Xu, Yu-Long Liang
Jian-Jing Liang, Department of Medicine, Hebei University, Baoding 071000, Hebei Province, China
Wen-Jing Feng, Run-Tao Xu, Yu-Long Liang, Department of General Surgery, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, Hebei Province, China
Ru Li, Department of Cardiology, First Hospital of Xinji City, Xinji 052300, Hebei Province, China
Author contributions: Liang JJ and Liang YL were responsible for the concept and writing of the manuscript; Liang JJ and Feng WJ analyzed the data; Feng WJ, Li R and Xu RT were responsible for collecting data and revising the paper; all authors have read and agreed to the published version of the manuscript.
Institutional review board statement: The study was reviewed and approved by Ethics Committee of the Third Hospital of Hebei Medical University.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu-Long Liang, MM, Associate Chief Physician, Associate Professor, Department of General Surgery, the Third Hospital of Hebei Medical University, No. 139 Ziqiang Road, Qiaoxi District, Shijiazhuang 050051, Hebei Province, China. yulongliang2020@163.com
Received: December 5, 2022
Peer-review started: December 5, 2022
First decision: December 26, 2022
Revised: January 4, 2023
Accepted: January 16, 2023
Article in press: January 16, 2023
Published online: February 16, 2023
Processing time: 70 Days and 21.1 Hours
ARTICLE HIGHLIGHTS
Research background

The incidence of thyroid cancer has increased worldwide over the past four decades, and thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for thyroid cancer has significantly improved the understanding of the molecular pathogenesis of thyroid cancer, thus allowing more personalized treatments for patients with thyroid cancer.

Research motivation

Thyroid-stimulating hormone is the major regulator and growth factor of the thyroid. However, the role of thyroid-stimulating hormones in thyroid cancer still needs further exploration.

Research objectives

The aim of this study is to examine the relationship between thyroid-stimulating hormone and thyroid cancer.

Research methods

75 patients with thyroid cancer were collected as the observation group and 50 healthy people as the control group. The control group was treated with thyroid replacement and the observation group was treated with thyroid-stimulating hormone inhibition. The levels of soluble interleukin (IL)-2 receptor (sIL-2R), IL-17, IL-35, free triiodothyronine (FT3), free tetraiodothyronine (FT4), CD3+, CD4+, CD8+, CD44V6, and tumor supplied group of factor (TSGF) were observed in the two groups.

Research results

After 4 wk of treatment, the levels of sIL-2R and IL-17 in the observation group were lower than those in the control group, while the levels of IL-35 were higher than those in the control group, with a statistically significant difference (P < 0.05). The levels of FT3, FT4, CD3+ and CD4+ in the observation group were higher than those in the control group, and the levels of CD8+, CD44V6, and TSGF in the observation group were lower than those in the control group.

Research conclusions

Thyroid-stimulating hormone inhibition therapy, as the best treatment method for thyroid cancer, can slow down the condition of patients and is worthy of clinical promotion.

Research perspectives

Thyroid-stimulating hormone is considered a risk factor for thyroid cancer, and thyroid hormone suppression therapy can reduce and control the progression of thyroid cancer. However, the effect of serum thyroid stimulating hormone may depend on the histological type of thyroid cancer. Therefore, in future research, we should focus on exploring the relationship between thyroid-stimulating hormones and different histological types of thyroid cancer.